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Abstract
To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and
psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.
A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or
intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted.
Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.9±12.5 years, disease duration 8.7±7.4 years).
Mean change in C-reactive protein level from baseline to week 12 was 11.2±4.0 (P< .001). Mean Disease Activity Index score
(DAS28) decreased from 5.5±1.0 at baseline to 2.7±1.3 (P< .001) at week 24. Mean change in Functional Assessment of Chronic
Illness Therapy score was5.4±11.2 points at week 24. Multiple regression analysis showed that the improvement in DAS28, sleep,
and depression explained 56% and 47% of fatigue variance at week 12 and 24, respectively.
Tocilizumab is effective in reducing disease activity and results in a clinically significant improvement in fatigue, pain, swollen joint
count, morning stiffness, sleepiness, depression, and DAS28; the last 3 were specifically identified as factors explaining fatigue
variance with the use of TCZ in RA patients.
Abbreviations: AEs = adverse events, BDI-II = Beck Depression Inventory, version II, CRP = C-reactive protein, DAS28 =
Disease Activity Index score, DMARDs = disease-modifying antirheumatic drugs, ESR = erythrocyte sedimentation rate, EULAR =
European League Against Rheumatism, FACIT-F = Functional Assessment Chronic Illness Therapy-Fatigue scale, HPA =
hypothalamic-pituitary-adrenal, IL = interleukin, PROs = patient-reported outcomes, RA = rheumatoid arthritis, SJC = swollen joint
count, TCZ = tocilizumab, TJC = tender joint count, SAEs = serious adverse events, TNF-alfa = tumor necrosis factor-alpha, VAS =
visual analog scale.
Keywords: clinical practice, fatigue, patient-reported outcomes, rheumatoid arthritis, tocilizumab
Editor: Ilke Coskun Benlidayi.
Funding: Economical support by Roche Farma S.A. Spain.
The authors have no conflicts of interest to disclose.
a Rheumatology Department, Hospital Sant Joan Despí Moises Broggi, b Department of Rheumatology, Hospital Vall d’Hebrón, c Department of Rheumatology, Hospital
Universitario de Bellvitge, L’Hospitalet de Llobregat, Barcelona, d Department of Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, e Department of
Rheumatology, Hospital General de l’Hospitalet, L’Hospitalet de Llobregat, f Department of Rheumatology, Complejo Hospitalario Cristal Piñor, Ourense, g Complejo
Hospitalario Arquitecto Marcide-Profesor Novoa Santos, A Coruña, h Department of Rheumatology, Xarxa Sanitaria i Social de Santa Tecla, Tarragona, i Department of
Rheumatology, Hospital General Universitario Santa María del Rosell, Cartagena, Murcia, j Department of Rheumatology, Corporació Sanitària Parc Taulí, Barcelona,
k Department of Rheumatology, Hospital da Costa Burela, Burela, Lugo, l Department of Rheumatology, Hospital Rafael Méndez, Lorca, Murcia, mDepartment of
Rheumatology, Hospital Universitari Sant Joan de Reus, Tarragona, n Department of Rheumatology, Clínica Girona, Girona, o Department of Rheumatology, Hospital de
Mollet, Mollet del Valles, Barcelona, pHospital Xeral Cies, Vigo, Pontevedra, qMedical Department, Roche Farma S.A., Spain.
∗
Correspondence: Héctor Corominas, Rheumatology and Autoimmune diseases Division, Hospital Sant Joan Despí Moisès Broggi, Carrer de Jacint Verdaguer, 90,
08970 Sant Joan Despí, Barcelona, Spain (e-mail: vancor@yahoo.com).
Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is
permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the
journal.
Medicine (2019) 98:26(e15947)
Received: 8 January 2019 / Received in final form: 9 May 2019 / Accepted: 14 May 2019
http://dx.doi.org/10.1097/MD.0000000000015947
Observational Study Medicine®
OPEN
1
1. Introduction
The clinical picture of rheumatoid arthritis (RA) includes the joint
and systemic involvement, and also several psychological aspects
may be affected. Importantly, fatigue is 1 of the most common
and disabling symptoms of RA. Although it is considered to
contribute to a decline in the patient’s health status and quality of
life, fatigue rarely constitutes a treatment target in RA.[1] Fatigue
has not been considered among the recommended criteria for RA
management, despite being a reliable and sensitive measure of
change in RA.[2]
The mechanisms for fatigue in RA are not entirely clear, as
most of current evidence is derived from cross-sectional studies
that do not allow identifying long-term predictors and potential
causal pathways for RA fatigue. Disease activity and other
disease-related factors such as excessive inflammation have been
reported to be correlated with fatigue.[3] However, the relation-
ship of fatigue to disease activity seems to be less strong than
previously assumed,[4–6] or this association has been found to be
secondary or indirectly mediated through pain.[4]
Discrepant findings have also been reported among those
studies evaluating pain as a possible cause of fatigue, whose
results vary from nonexistent[7,8] to a strong correlation based on
cross-sectional and longitudinal studies.[9] The inflammatory
process as a factor influencing RA fatigue has not been fully
established, as weak associations between fatigue and erythrocyte
sedimentation rate (ESR), tender and swollen joints, and Disease
Activity Index score (DAS28), or even absent for rheumatoid
factor, ESR, and hemoglobin levels, have been described.[10–12]
Psychological factors seem to play a crucial role in explaining
fatigue.[4,6,8,12] The contribution of disease activity to fatigue has
been explained by mechanisms of mood and sleep disorders.[13]
These findings support the widely accepted model of multifacto-
rial etiology for fatigue, which has recently incorporated personal
life aspects as factors that may be inter or intrarelated with other
RA disease factors, and behavioral/cognitive issues.[14]
Tocilizumab (TCZ) has demonstrated drug efficacy and a
safety profile in RA formore than 8 years to date. Considering the
complexity of fatigue in RA, it is difficult to obtain conclusive
data regarding the effect of treatment on this symptom.[15] Relief
of fatigue in RA patients receiving interleukin (IL)-6 blocking
agents,[16,17] suggests a biological pathway target for these agents
through the hypothalamic-pituitary-adrenal (HPA) axis, given its
activation by IL-6.[18,19] The fact that disturbance of the HPA
axis may also influence other RA symptoms[18] led us to the
hypothesis that a possible change in fatigue with the anti-IL-6
receptor antibody TCZ may be explained not only through its
effect on disease activity but also on other RA-related, and
physical and psychosocial factors.
The aim of the ACT-AXIS study was to assess efficacy of TCZ
on disease activity and to identify factors associated with fatigue,
and other clinical and psychological disease-related factors in
patients with RA treated with TCZ after failure or intolerance to
disease-modifying antirheumatic drugs (DMARDs) or tumor
necrosis factor (TNF)-inhibitors.
2. Methods
2.1. Study design
The ACT-AXIS study was a multicenter, prospective observa-
tional study conducted in rheumatology units of 15 Spanish
hospitals. The study was conducted in accordance with the
Declaration of Helsinki and national regulations. The study was
approved by the Ethic Committee of the Hospital de Sant Joan
Despí Moisès Broggi, Barcelona (Spain), and all patients gave
their written informed consent. Patients were followed up for 24
weeks according to clinical practice.
2.2. Study population
Inclusion criteria: adult (age≥18 years) patients with moderate to
severe RA (fulfilling the American College of Rheumatology
1987 revised criteria for RA), nonresponders or intolerant to
DMARDs or TNF-inhibitors, and for whom the rheumatologist
had decided to initiate TCZ treatment according to routine
clinical practice. Exclusion criteria: previous diagnostic of
depression or other psychiatric condition, and exclusion of other
inflammatory or autoimmune diseases. Administration of TCZ
as clinical trial medication or compassionate therapy, an absolute
neutrophil count 2109/L in the last routine blood test
available, and inability to complete the study questionnaires were
the exclusion criteria.
2.3. Data collection and assessments
Baseline evaluation at the time of TCZ initiation included a
complete medical history along with the following data that were
also collected at baseline and at 2 routine follow-up visits closest
to weeks 12 and 24: laboratory parameters (hemoglobin,
hematocrit, C-reactive protein [CRP] and ESR), RA activity-
related data (tender joint count [TJC], swollen joint count [SJC],
DAS28 score, patient’s global assessment of disease activity,
physician’s global assessment of disease activity, patient’s pain
assessment, morning stiffness duration, fatigue, sleepiness, and
depression), and personal and social aspects of life (marital
status, children living at home, care for dependents employment
status, significant events in life, duration of sleep [hours of sleep at
night], and physical activity). Moreover, TCZ treatment-related
data and adverse events were retrieved at routine monthly visits
coinciding with TCZ administration.
The DAS28 was calculated for disease activity using the
ESR,[20] and it ranges from 0 to 10, where a score above 5.1
indicates high disease activity, a score 3.2 to 5.1 represents
moderate disease activity, and below 3.2 indicates low disease
activity. Response to TCZ treatment was evaluated by the
European League Against Rheumatism (EULAR) response
criteria.[21] Patient’s and physician’s global assessment of disease
activity and pain were evaluated using a 10-cm visual analog
scale (VAS). Fatigue was assessed according to the Functional
Assessment Chronic Illness Therapy-Fatigue scale (FACIT-F,
version 4)[22]; a brief 13-item score ranged from 0 to 52, where a
high score represents less fatigue and a 3 to 4-point change is
considered clinically significant. Depression was measured using
the Beck Depression Inventory, version II (BDI-II),[23,24] which
contains 21 questions scored on a scale value of 0 (neutral) to 3
(maximal severity). Total scores range from 0 to 63, and a higher
total score corresponds to more severe depressive symptoms. A
total score over 18 indicates moderate to severe depression.
Sleepiness was evaluated by the Epworth Sleepiness Scale,[25]
which is intended to evaluate the probability of falling asleep in 8
situations reflecting activities of daily living in a score from 0
“never doze or sleep” to 3 “high chance of dozing or sleeping.”
Total score ranges from 0 to 24, where the higher the score, the
higher the sleepiness level.
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2.4. Statistical analysis
The primary endpoint was to evaluate the correlation between
change in fatigue and disease-related factors (serum hemoglobin
levels, SJC, morning stiffness, pain, sleepiness, and depression)
with the use of TCZ. We also seek for the influence of personal
aspects (marital status, children living at home, care for
dependents, employment status, important events in life, physical
activity, time in hours of sleep at night) on the changes described.
A simple linear regression model was used to calculate the
individual correlation. The change in fatigue (from baseline to
weeks 12 and 24) as the dependent variable was regressed against
the change in each of the abovementioned disease-related
variables, and personal and social aspects to assess the individual
correlation. All variables that had a significance level of P .10
were subsequently included in a multivariate linear regression
analysis using an automatic stepwise selection model to identify
the factors explaining fatigue variance. The b-regression
coefficient, beta standardized regression coefficient, and the
coefficient of determination (R2) were calculated, the latter to
determine the variance of change in fatigue explained by the
independent variables included in the model.
Secondary endpoints included changes from baseline to week
12 and 24 for hemoglobin and CRP levels, SJC, pain score,
morning stiffness duration, fatigue, sleepiness, and depression
scores. We also evaluated the potential correlation between
fatigue and anemia, defined as hemoglobin levels <12g/dL in
women and<13g/dL in men. CRP, SJC, and DAS28 values were
used to assess disease activity and response to the treatment.
Clinical efficacy was assessed by a decrease in DAS28 score from
baseline to weeks 12 and 24, and EULAR responses. Remission
was defined, in accordance with the EULAR definition, as DAS28
<2.6. Safety was assessed by the frequency, severity, and
causality of adverse events (AEs) reported during the study
period.
Only patients with FACIT questionnaires scores available at
baseline and 12 and 24 weeks after treatment initiation were
considered evaluable for the effectiveness analysis.
Descriptive analysis was used for secondary endpoints, with
continuous variables expressed as either mean± standard devia-
tion (SD) or as median (interquartile range) according to their
distribution, and categorical variables as percentage. The change
in each variable from baseline to week 12 and 24 was calculated
by paired-samples t test (parametric) or Wilcoxon signed-rank
tests (nonparametric).
The statistical analyses were performed with the Statistical
Package for the Social Sciences (SPSS) version 17.0 (SPSS Inc,
Chicago, IL).
3. Results
3.1. Patient characteristics
Between September, 2012 andMay, 2015, a total of 122 patients
were enrolled in the study. Two patients were excluded from the
study since they did not meet selection criteria. Thirty-five
patients were excluded from the effectiveness analysis due to the
lack of FACIT questionnaire scores at any of the study visits.
Therefore, the evaluable population for the effectiveness analysis
comprised a total of 85 patients. Premature withdrawal from the
study occurred in 4 patients. The patient flowchart is shown in
Fig. 1. Patient demographic and clinical baseline characteristics
are described in Table 1.
3.2. Tocilizumab treatment
Most patients received TCZ at a dose of 8mg/kg. Ten (11.8%)
patients required treatment dose adjustments due to laboratory
abnormalities (n=4), weight gain (n=7), adverse events (n=1),
and other unspecified reasons (n=3). Of these, 8 patients
required 1 or 2 dose modifications. Six (7.1%) patients
required at least 1 temporary interruption of TCZ, mainly due
to adverse events (n=4). During the 24-week period, 4 (4.7%)
patients discontinued TCZ due to insufficient response (n=3)
and adverse events (n=1). The majority of patients received
TCZ combined with MTX for RA (91.8%), and at that time
point of the analysis, 68 patients were receiving low doses of
prednisone (<5 m/daily).
3.3. Clinical efficacy of tocilizumab
The SJC and CRP levels were significantly reduced after 12 weeks
of TCZ treatment (mean change from baseline of 4.0±4.7
[P< .001] and 11.2±4.0 [P< .001], respectively). By week 24,
mean baseline DAS28 had decreased 2.7±1.4 points (P< .001)
(Table 2). In addition, after 24 weeks of TCZ initiation, EULAR
responses were good in 44 (62.0%) patients, moderate in 22
(31.0%) patients, and absent in 5 (7%). The proportion of
patients who experienced disease remission within 24 weeks was
45.2% (Fig. 2).
3.4. Effect of tocilizumab on fatigue and RA-related
factors in active RA
After 24 weeks of TCZ, there was a clinically significant mean
change in FACIT-F score of 5.4±11.2 points from baseline
(P< .001) (Table 2). Patients with significant fatigue (FACIT-F
score <30) decreased from 58.8% at baseline to 37.6% by week
24.
Hemoglobin levels significantly increased in 0.6±1.1 points by
week 24 (P< .001). Accordingly, patients with anemia decreased
from 65.9% at baseline to 47.9% at week 24. Mean scores for
pain and depression, and mean duration of morning stiffness
were significantly reduced by week 12, with a mean change that
was sustained at week 24 (Table 2).
3.5. RA-related factors that may contribute to fatigue in
RA
Simple linear regression analysis showed that change on FACIT-F
score seen was significantly correlated with change in DAS28e
(b=3.241, P< .01), pain (b=0.947, P= .037), sleepiness
(b=0.742, P= .003), and depression (b=0.714, P< .001) at
week 12.
When the association with change in FACIT-F score at week 24
was analyzed, significant correlations were observed with the
change in DAS28 (b=2.596, P< .01), SJC (b=0.600,
P= .022), pain (b=0.838, P= .044), sleepiness (b=1.193,
P= .001), and depression scores (b=0.777, P< .001).
Fatigue outcomewas associated neither with hemoglobin levels
and morning stiffness duration, nor with any of the personal life
aspects.
Multiple linear regression analysis showed that the indepen-
dent change in DAS28, sleepiness depression scores explained
56% and 47% of fatigue variance at weeks 12 and 24,
respectively (Table 3).
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3.6. Safety
In all, 120 patients were included in the safety analysis. Overall,
195 AEs were reported in 77 (64.2%) patients. Most adverse
events were mild (76.9%) to moderate (20.5%), and 48 AEs were
considered as related to TCZ in 28 (23.3%) patients.
Hypercholesterolemia and hypertransaminasemia were the most
common adverse reactions in 11 (9.2%) and 4 (3.3%) patients,
respectively. Only 3 patients experienced treatment-related
infections. Infusion-related adverse reactions occurred in 7
(5.8%) patients. Seven (3.6%) serious AEs (SAEs) were reported
in 6 patients: infectious arthritis, pilonidal cyst, acute endocardi-
tis, acute pyelonephritis, respiratory tract infection, respiratory
failure, and rheumatoid lung disease.
4. Discussion
To our knowledge, this is the first study focusing on the
correlation of fatigue with other disease-related and psychosocial
factors in patients with RA treated with TCZ in routine clinical
practice. Our findings show that TCZ results in a clinically
significant improvement in fatigue in patients with moderate to
severe RA. Fatigue outcome was significantly correlated with
improvement in SJC, DAS28, pain, sleepiness, and depression
after TCZ treatment, although only depression, sleepiness, and
DAS28 seemed to explain fatigue variance.
The efficacy data show that TCZ is effective in reducing disease
activity,[26–28] as reflected by the significant decrease in DAS28, in
line with clinical trials with this targeted treatment.[26–28] In
addition, high remission levels were achieved by week 12 that
were maintained and even slightly increased after 24 weeks from
treatment initiation. The notable decrease in SJC and CRP levels
also revealed a significant improvement in initial inflammatory
activity. The high remission rates observed are those expected
considering the beneficial effect of TCZ on acute-phase
reactants.[29] In addition, we found that hemoglobin levels
increased significantly after TCZ therapy as previously seen.[30]
Figure 1. Disposition of patients. Flowchart diagram of the number of patients included in the study.
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The increase in hemoglobin levels could be reflecting declines in
hepcidin after TCZ, which previous research has associated with
an improvement of inflammatory anemia together with CRP
reductions.[31] Our findings therefore support the beneficial effect
of TCZ in decreasing inflammatory activity and improving
functioning in patients with active RA under routine clinical
practice conditions.
Consistent with previous efficacy reports,[27,32] we found that
TCZ treatment resulted in a clinically significant improvement in
fatigue (≥4 points in FACIT-F)[33] that was even enhanced over
time. Accordingly, the high proportion of RA patients with
significant fatigue decreased approximately 20% by week 24.
Patient-reported outcomes (PROs) on pain, morning stiffness, and
depression were notably improved by week 12, and the beneficial
effect was sustained over time. Despite the association of disease
activity with morning stiffness,[34] pain, and depression,[35,36] we
cannot conclude that the improved PROs are derived from the
reduction in disease activity after TCZ treatment. Morning
stiffness and pain have been linked to high levels of IL-6 during
early morning in patients with active RA.[37,38] Additionally,
depression in RA has been reported to be mediated by the up-
regulation of cytokines known tobe associated to theHPAaxis.[39]
Thepotential effect ofTCZto inhibit IL-6may therefore contribute
to its efficacy in reducing these symptoms, providing both clinical
and psychosocial benefit in significantly fatigued patients.
Our findings show that fatigue outcome was significantly
correlated with improvement in disease activity measured by
DAS28 and SJC, and also with pain, sleepiness, and depression
after TCZ treatment, although only DAS28, sleepiness, and
Table 1
Baseline demographics, clinical characteristics, and PROs (n=85).
Characteristics Value
Age, y (mean±SD) 51.9±12.5
Female; n (%) 72 (84.7)
Duration of RA, y (mean±SD) 8.7±7.4
ESR, mm/h (mean±SD)
∗
44.8±26.3
CRP, mg/dL (mean±SD)† 13.0±19.0
Hemoglobin, g/dL (mean±SD) 12.5±1.5
Tender joint count (mean±SD) 8.8±6.9
Swollen joint count (mean±SD) 6.0±4.6
DAS28 (mean±SD)‡ 5.5±1.0
Tociluzumab in combination with MTX 91.8 (%)
Patient’s global assessment (VAS), cm (mean±SD) 6.8±2.1
Physician’s global assessment (VAS), cm (mean±SD) 6.0±2.1
Pain VAS, cm (mean±SD) 6.6±2.3
Morning stiffness, h (mean±SD) 1.4±2.7
FACIT-F fatigue score (mean±SD) 26.8±12.4
Epworth sleepiness score (mean±SD) 6.0±4.6
Beck Depression Score (mean±SD) 17.2±11.8
CRP=C-reactive protein, DAS28=Disease Activity Index score, ESR= erythrocyte sedimentation
rate, FACIT-F= Functional Assessment Chronic Illness Therapy-Fatigue scale, PROs=patient-
reported outcomes, RA= rheumatoid arthritis, SD= standard deviation, VAS= visual analog scale.
∗
Missing data (n=4).
†Missing data (n=10).
‡Missing data (n=4).
Table 2
Mean changes in fatigue and RA disease factors from baseline to
12 and 24 weeks.
Variable Week 12 P
∗
Week 24 P
∗
Fatigue (FACIT-F score) 4.6±10.5 <.001 5.4±11.2 <.001
Hemoglobin levels (g/dL) 0.7±1.0 <.001 0.6±1.1 <.001
CRP (mg/L) 11.2±4.0 <.001 12.5±21.3 <.001
SJC 4.0±4.7 <.001 4.2±4.7 <.001
DAS28 2.5±1.2 <.001 2.7±1.4 <.001
Morning stiffness (h) 0.9±2.9 <.001 1.0±2.7 <.001
Pain VAS (cm) 2.6±2.5 <.001 2.6±3.0 <.001
Epworth sleepiness score 0.4±4.5 .172 0.8±3.4 <.05
Beck Depression Score 3.1±9.1 <.001 3.5±9.0 <.005
CRP=C-reactive protein, FACIT= Functional Assessment Chronic Illness Therapy-Fatigue scale,
SJC= swollen joint count, VAS= visual analog scale.
∗
Based on paired-samples t test.
Figure 2. Disease activity over time. Disease activity was assessed according to DAS28 score. Percentage of patients achieving remission, low, moderate and high
disease activity according to EULAR criteria are exposed: remission: DAS28<2.6, low disease activity: 2.6<DAS28 3.2, moderate disease activity: 3.2<DAS28
 5.1, high disease activity: DAS28 >5.1. DAS28=Disease Activity Index score, EULAR=European League Against Rheumatism.
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depression were retained in the multivariate model as factors
explaining the variance in fatigue. The correlation of fatigue with
disease activity is consistent with recent evidence.[40] However,
the relationship of disease activity with fatigue in RA is unclear,
and data available on this issue primarily come from cross-
sectional studies,[41–44] while prospective evidence is scarce.[8]
The change in SJC was not identified as a contributor factor to
fatigue in multivariate models performed in our series. These
findings are in line with studies reporting that inflammatory
components of the DAS28 contribute minimally to fatigue.[12] In
addition, we found that other inflammatory parameters such as
hemoglobin levels did not appear to be related to fatigue in line
with previous reports.[6] Consistent with previous evidence,
fatigue outcome appears to be independent of anemia.[40]
Regarding pain caused by joint inflammation, the bivariate
analyses showed a significant correlation of pain with fatigue,
although the multiple regression models did not identify pain as a
factor explaining fatigue variance as seenwith SJC. This finding is
contrary to most cross-sectional studies conducted so far,[6,43,45]
but consistent with a previous prospective study identifying
predictors of fatigue over 1 year among RA patients.[8]
Taken together, these data suggest that fatigue variance after
TCZ does not seem to be only explained by inflammatory
activity, but physical and emotional functioning appear to have a
greater contribution in our model as previously seen.[6,43]
Accordingly, disease activity measured by DAS28 seemed to
be contributing less strongly to fatigue variance than sleepiness
and depression in the study multivariate models. At both study
time points, sleepiness and depression explained variability in
fatigue the best, depression being a stronger contributor. Our
findings are therefore in line with previous studies that reported a
significant association between fatigue variability and sleep
quality or sleep disturbances.[6,46] However, it should be taken
into account that the mean baseline sleepiness score is 6 and
therefore RA patients evaluated in our series did not suffer from
sleepiness because the Epworth scale considers a score between 0
and 9 as normal, and a mean reduction of about 1 point after 24
weeks is still within the normal range. In addition, duration of
sleep was not found to be correlated with fatigue outcome. We
cannot therefore clearly associate improvement in fatigue with
changes in sleepiness score, despite its potential association.
Regarding cognitive and emotional functioning, depression
was found to be strongly associated with fatigue, consistent with
previous reports.[6,43] It is noteworthy that the mean baseline
depression score in our series is nearly 18 and therefore patients
had symptoms of moderate to severe depression. The baseline
depressive mood of patients may be explained by their clinical
activity at the time of TCZ treatment initiation, with high
baseline disease activity (DAS28) and ESR scores, and a negative
global perception of their disease (baseline VAS 6.6). Thus, the
negative perception of disease may have contributed to fatigue
through the mood state as these significantly fatigued RA patients
(mean baseline FACIT <30) may perceive fatigue as frustrating
or exhausting as previously seen.[6] The quality of life of patients
with arthritis was previously investigated in several observational
studies showing that all measures of disease activity and self-
efficacy scores were markedly better in patients receiving biologic
versus conventional therapy.[47] Therefore, improvement in
depressive symptoms through the effect of TCZ on IL-6 levels
may also improve fatigue. However, whether depression is the
major cause of the improvement in fatigue in active RA cannot be
clearly concluded as other psychosocial factors may be involved
in RA fatigue besides depression.[8]
Finally, TCZ was reported to be well-tolerated with a
withdrawal percentage due to adverse events <1%. The safety
profile of TCZ presented no new or unexpected safety signals.
Themost common SAEs were infections as previously reported in
clinical trials with TCZ.[26–28,48–50]
Some limitations of our study should be pointed out. Firstly,
even though the change in sleepiness was identified as a
contributor to fatigue improvement in the multivariate analyses,
patients evaluated in our series did not suffer from sleepiness at
that time point. Therefore, whether TCZ may reduce fatigue
through the improvement of sleepiness would need to be
addressed in RA patients with sleep disturbances. Secondly,
our correlation analyses performed included relevant physical
and psychosocial factors in addition to disease activity measures
that have been involved in explaining fatigue in previous cross-
sectional studies. However, we acknowledge that some inflam-
matory component such as CRP, ESR, and TJC, and other
variables associated with RA fatigue such as disability and
functioning, health-related quality of life, or self-efficacy were not
Table 3
Factors associated with fatigue in RA by multiple regression analysis.
Variable b-coefficient
∗
Beta† 95% CI P
Change from baseline to week 12‡
DAS28 score 2.200 0.251 3.741 to 0.658 <.01
Epworth sleepiness score 0.944 0.381 1.371 to 0.518 <.001
Beck depression score 0.707 0.590 0.919 to 0.494 <.001
Constant term 2.822
R2=0.558
Change from baseline to week 24x
DAS28 score 1.743 0.215 3.242 to 0.244 <.05
Epworth sleepiness score 0.990 0.256 1.694 to 0.285 <.001
Beck depression score 0.658 0.517 0.896 to 0.419 <.001
Constant term 2.470
R2=0.473
CI= confidence interval.
∗
Unstandardized coefficient.
† Standardized coefficient.
‡ Factors from the initial simple linear regression analysis with P .10 included in the multivariate linear regression analysis: change in DAS28, pain, sleepiness, and depression scores.
x Factors from the initial simple linear regression with P .10 included in the multivariate regression analysis: change in DAS28, SJC, pain, sleepiness, and depression scores.
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assessed in our model, or were not evaluated through a specific
instrument. Other limitations to be highlighted are that RA is a
heterogeneous disease and multiple comorbidities, and the
requirement of drugs could affect some subjective complaints
in different scores evaluated.
Despite its limitations, this study offers a welcome addition to
the limited available prospective data on factors associated with
RA fatigue, given that most evidence comes from cross-sectional
studies. Additionally, the data existing on RA fatigue-related
factors are heterogeneous mainly due to the use of different scales
and questionnaires to evaluate fatigue and other PROs in
addition to the assessment of different sets of variables in
correlation studies. In this scenario, our study may provide the
basis for a better understanding of factors explaining fatigue.
According to this, a recent paper on therapeutic strategies in
patients affected by autoimmune rheumatic diseases will help
in the near future to improve the unmet needs in the
management of patients with RA.[51] Overall, we confirm this
study supports and provides further evidence on the efficacy
and safety of TCZ in clinical and psychological aspects in the
real-world setting.
5. Conclusions
In summary, TCZ treatment results in a clinically significant
improvement in fatigue that seems to correlate with disease
activity reduction, although improvements in sleep and depres-
sive symptoms appear to be stronger contributors to fatigue
variance. Psychosocial factors therefore seem to have a more
important role than inflammatory-related factors in explaining
fatigue in active RA. Measuring the symptoms of fatigue in RA
and individualization of therapeutic management based on mood
state and depressive symptoms may therefore be of paramount
importance in clinical practice, given that fatigue may be a
reliable and feasible target to improve patient outcome.
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